8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Feb 11, 2026·SEC
Royalty Pharma plc(RPRX)Earnings, Financials & Key Ratios
RPRX•NASDAQ
29.4× P/E·Price updated Jun 19, 2026
AboutRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Show more
- Revenue$2.38B+5.1%
- EBITDA$1.56B+0.5%
- Net Income$771M-10.2%
- EPS (Diluted)1.80-5.8%
- Gross Margin100%
- EBITDA Margin65.74%-4.4%
- Operating Margin65.58%+14.8%
- Net Margin32.42%-14.6%
- ROE7.69%-8.6%
RPRX Key Insights
Royalty Pharma plc (RPRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 104.7% free cash flow margin
- ✓Momentum leader: RS Rating 81 (top 19%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 5.8% through buybacks
- ✓Healthy 5Y average net margin of 29.5%
✗Weaknesses
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RPRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RPRX Price & Volume
Royalty Pharma plc (RPRX) stock price & volume — 10-year historical chart
Loading chart...
RPRX Growth Metrics
Royalty Pharma plc (RPRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years2.3%
3 Years2.06%
TTM7.82%
Profit CAGR
10 Years-
5 Years-4.59%
3 Years162.07%
TTM-24.25%
EPS CAGR
10 Years-
5 Years7.06%
3 Years162.07%
TTM-23.71%
Return on Capital
10 Years10.2%
5 Years7.27%
3 Years8.61%
Last Year8.68%
RPRX Recent Earnings
Royalty Pharma plc (RPRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$1.30+7.4%
$1.21
Rev
$925M+4.9%
$882M
Q1 2026
Feb 11, 2026Metric
Actual
Est
EPS
$1.46+13.2%
$1.29
Rev
$874M+8.3%
$807M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$1.17+17.7%
$0.99
Rev
$609M-15.1%
$717M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$1.14+10.7%
$1.03
Rev
$579M-14.0%
$673M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $1.30vs $1.21+7.4% | $925Mvs $882M+4.9% |
| Q1 2026 | Feb 11, 2026 | $1.46vs $1.29+13.2% | $874Mvs $807M+8.3% |
| Q4 2025 | Nov 5, 2025 | $1.17vs $0.99+17.7% | $609Mvs $717M-15.1% |
| Q3 2025 | Aug 6, 2025 | $1.14vs $1.03+10.7% | $579Mvs $673M-14.0% |
Based on last 12 quarters of dataView full earnings history →
RPRX Peer Comparison
Royalty Pharma plc (RPRX) competitors in Royalty and IP Monetization Vehicles — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 OR | 6.53B | 34.86 | 31.41 | 47.52% | 78.1% | 16.55% | 0.01 | |
 WPM | 55.66B | 122.57 | 37.26 | 83.33% | 65.55% | 21.33% | 0.00 | |
 RGLD | 14.91B | 214.82 | 32.11 | 44.57% | 48.53% | 11.85% | 0.13 | |
 FNV | 42.27B | 219.26 | 37.42 | 63.69% | 65.12% | 18.68% | 0.00 | |
 XOMA | 525.34M | 41.89 | 28.69 | 83.06% | 86.97% | 30.21% | 1.27 | |
 DRI | 25.27B | 213.45 | 24.09 | 6.03% | 8.66% | 50.71% | 2.70 | |
 EPD | 79.12B | 36.60 | 13.76 | -6.44% | 11.03% | 19.29% | 1.14 |
Compare RPRX vs Peers
Royalty Pharma plc (RPRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RPRX Income Statement
Royalty Pharma plc (RPRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.6B | 1.79B | 1.81B | 2.12B | 2.29B | 2.24B | 2.35B | 2.26B | 2.38B | 2.44B |
Revenue Growth % | - | 12.33% | 1.08% | 16.98% | 7.87% | -2.28% | 5.24% | -3.86% | 5.06% | 7.82% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 1.6B▲ 0% | 1.79B▲ 12.3% | 1.81B▲ 1.1% | 2.12B▲ 17.0% | 2.29B▲ 7.9% | 2.24B▼ 2.3% | 2.35B▲ 5.2% | 2.26B▼ 3.9% | 2.38B▲ 5.1% | 1.81B▲ 0% |
Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 74.15% |
Gross Profit Growth % | - | 12.33% | 1.08% | 16.98% | 7.87% | -2.28% | 5.24% | -3.86% | 5.06% | - |
Operating Expenses | 658.24M | 430.45M | -808.92M | 526.95M | 858.75M | 1.93B | 862.4M | 971.13M | 818.67M | 983.61M |
OpEx % of Revenue | 41.19% | 23.98% | -44.59% | 24.83% | 37.51% | 86.27% | 36.63% | 42.9% | 34.42% | - |
Selling, General & Admin | 106.44M | 61.91M | 103.44M | 181.72M | 182.83M | 227.3M | 249.75M | 236.67M | 573.48M | 621.77M |
SG&A % of Revenue | 6.66% | 3.45% | 5.7% | 8.56% | 7.99% | 10.16% | 10.61% | 10.46% | 24.11% | - |
Research & Development | 117.87M | 392.61M | 83.04M | 26.29M | 200.08M | 177.11M | 52M | 2M | 452M | 442M |
R&D % of Revenue | 7.38% | 21.87% | 4.58% | 1.24% | 8.74% | 7.92% | 2.21% | 0.09% | 19.01% | - |
Other Operating Expenses | 433.93M | -24.07M | -995.4M | 318.95M | 475.84M | 1.53B | 560.66M | 732.46M | -206.81M | 1000K |
Operating Income | 939.69M▲ 0% | 1.36B▲ 45.2% | 2.62B▲ 92.3% | 1.6B▼ 39.2% | 1.43B▼ 10.3% | 307.06M▼ 78.5% | 1.49B▲ 385.9% | 1.29B▼ 13.4% | 1.56B▲ 20.7% | 1.59B▲ 0% |
Operating Margin % | 58.81% | 76.02% | 144.59% | 75.17% | 62.49% | 13.73% | 63.37% | 57.1% | 65.58% | 65.07% |
Operating Income Growth % | - | 45.2% | 92.25% | -39.18% | -10.32% | -78.54% | 385.94% | -13.38% | 20.66% | - |
EBITDA | 972.96M | 1.4B | 2.65B | 1.62B | 1.45B | 312.74M | 1.89B | 1.56B | 1.56B | 1.54B |
EBITDA Margin % | 60.89% | 77.87% | 145.91% | 76.26% | 63.5% | 13.98% | 80.15% | 68.76% | 65.74% | 63.1% |
EBITDA Growth % | - | 43.66% | 89.39% | -38.86% | -10.18% | -78.49% | 503.47% | -17.54% | 0.45% | -23.56% |
D&A (Non-Cash Add-back) | 33.27M | 33.27M | 23.92M | 23.06M | 23M | 5.67M | 0 | 0 | 3.85M | 2.47M |
EBIT | 1.59B | 1.8B | 2.73B | 1.86B | 1.41B | 418.02M | 1.89B | 1.56B | 1.63B | 1.13B |
Net Interest Income | -240.58M | -255.51M | -246.24M | -128.68M | -112.61M | -109.63M | -114.9M | -178.17M | -274.07M | -314.1M |
Interest Income | 6.76M | 24.44M | 22.33M | 28.38M | 53.53M | 78.33M | 72.29M | 47.34M | 33.59M | 22.3M |
Interest Expense | 247.34M | 279.96M | 268.57M | 157.06M | 166.14M | 187.96M | 187.19M | 225.51M | 307.66M | 336.4M |
Other Income/Expense | 403.49M | 153.41M | -161.76M | 106.56M | -189.51M | -77M | 207.94M | 38.37M | -235.33M | -229.58M |
Pretax Income | 1.34B▲ 0% | 1.52B▲ 13.0% | 2.46B▲ 62.2% | 1.7B▼ 30.9% | 1.24B▼ 27.1% | 230.06M▼ 81.5% | 1.7B▲ 639.0% | 1.33B▼ 21.7% | 1.32B▼ 0.5% | 1.36B▲ 0% |
Pretax Margin % | 84.06% | 84.57% | 135.67% | 80.19% | 54.21% | 10.28% | 72.2% | 58.79% | 55.68% | 55.67% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 173M |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 12.73% |
Net Income | 1.21B▲ 0% | 1.38B▲ 13.9% | 2.35B▲ 70.5% | 975.04M▼ 58.5% | 619.73M▼ 36.4% | 42.83M▼ 93.1% | 1.13B▲ 2549.5% | 858.98M▼ 24.3% | 770.95M▼ 10.2% | 827.6M▲ 0% |
Net Margin % | 75.72% | 76.76% | 129.45% | 45.94% | 27.07% | 1.91% | 48.2% | 37.95% | 32.42% | 33.9% |
Net Income Growth % | - | 13.86% | 70.46% | -58.48% | -36.44% | -93.09% | 2549.5% | -24.31% | -10.25% | -24.25% |
Net Income (Continuing) | 1.34B | 1.52B | 2.46B | 1.7B | 1.24B | 230.06M | 1.7B | 1.33B | 1.32B | 1.19B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 63.87M | 35.88M | 5.08B | 4.47B | 3.9B | 3.56B | 3.4B | 3.24B | 3.05B |
EPS (Diluted) | 3.42▲ 0% | 3.89▲ 13.7% | 6.63▲ 70.4% | 1.28▼ 80.7% | 1.49▲ 16.4% | 0.10▼ 93.3% | 2.53▲ 2430.0% | 1.91▼ 24.5% | 1.80▼ 5.8% | 1.48▲ 0% |
EPS Growth % | - | 13.74% | 70.44% | -80.69% | 16.41% | -93.29% | 2430% | -24.51% | -5.76% | -23.71% |
EPS (Basic) | 3.42 | 3.89 | 6.63 | 1.28 | 1.49 | 0.10 | 3.41 | 1.92 | 2.33 | - |
Diluted Shares Outstanding | 354.18M | 354.18M | 354.18M | 388.13M | 414.8M | 564.93M | 602.9M | 594M | 559.61M | 559.61M |
Basic Shares Outstanding | 354.18M | 354.18M | 354.18M | 388.13M | 414.79M | 437.96M | 447.6M | 445.99M | 431.89M | 431.89M |
Dividend Payout Ratio | 60.76% | 59.11% | 31.48% | 40.8% | 46.02% | 778.21% | 31.58% | 43.83% | 49.06% | - |
RPRX Balance Sheet
Royalty Pharma plc (RPRX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 2.95B | 2.61B | 832.07M | 2.7B | 2.88B | 2.55B | 1.27B | 1.8B | 619M | 1.43B |
Cash & Short-Term Investments | 1.38B | 2.39B | 793.21M | 2.65B | 2.8B | 2.43B | 1.23B | 1.77B | 637.5M | 608.29M |
Cash Only | 1.38B | 1.92B | 246.2M | 1.01B | 1.54B | 1.71B | 477.01M | 929.03M | 618.7M | 586.39M |
Short-Term Investments | 0 | 461.82M | 547.01M | 1.64B | 1.26B | 717.04M | 756.74M | 841.97M | 18.8M | 21.9M |
Accounts Receivable | 0 | 198.63M | 38.77M | 39.17M | 68.31M | 36.6M | 22.41M | 26.96M | 883.7M | 807.36M |
Days Sales Outstanding | - | 40.39 | 7.8 | 6.74 | 10.89 | 5.97 | 3.47 | 4.35 | 135.63 | 97.49 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 1.57B | 23.89M | 92K | 8.6M | 6.63M | 90.52M | 18.04M | 4.19M | -902.2M | 10.16M |
Total Non-Current Assets | 8.43B | 8.76B | 11.62B | 13.32B | 14.64B | 14.26B | 15.11B | 16.42B | 17.06B | 18.39B |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 493.12x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 924.63M | 924.63M |
Intangible Assets | 0 | 75.65M | 51.72M | 28.67M | 5.67M | 0 | 0 | 15.13B | 0 | 16.54B |
Long-Term Investments | 0 | 8.67B | 11.48B | 13.28B | 14.63B | 14.23B | 15.1B | 16.39B | 171.31M | 18.24B |
Other Non-Current Assets | 0 | 19.11M | 87.95M | 10M | 4.14M | 29.63M | 6.52M | -15.09B | 15.97B | 76.85M |
Total Assets | 11.37B▲ 0% | 11.37B▼ 0.0% | 12.45B▲ 9.5% | 16.02B▲ 28.7% | 17.52B▲ 9.3% | 16.81B▼ 4.0% | 16.38B▼ 2.6% | 18.22B▲ 11.2% | 19.62B▲ 7.7% | 19.82B▲ 0% |
Asset Turnover | 0.14x | 0.16x | 0.15x | 0.13x | 0.13x | 0.13x | 0.14x | 0.12x | 0.12x | 0.13x |
Asset Growth % | - | -0.03% | 9.5% | 28.68% | 9.34% | -4.01% | -2.57% | 11.24% | 7.67% | 31.22% |
Total Current Liabilities | 383.41M | 580.17M | 333.42M | 307.89M | 171.25M | 1.17B | 161.38M | 1.25B | 636.21M | 535.68M |
Accounts Payable | 0 | 4.48M | 11.18M | 10.78M | 5.62M | 7.91M | 15.16M | 13.37M | 19.4M | 25.48M |
Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - |
Short-Term Debt | 280.93M | 281.44M | 281.98M | 0 | 0 | 997.51M | 0 | 997.77M | 380M | 380M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 102.48M | 0 | 9.21M | 18.6M | 0 | 12.4M | 11.38M | 68.6M | 163.98M | 130.2M |
Current Ratio | 7.69x | 4.50x | 2.50x | 8.76x | 16.81x | 2.19x | 7.90x | 1.44x | 0.97x | 2.66x |
Quick Ratio | 7.69x | 4.50x | 2.50x | 8.76x | 16.81x | 2.19x | 7.90x | 1.44x | 0.97x | 2.66x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 97.49 |
Total Non-Current Liabilities | 6.52B | 6.24B | 5.98B | 5.82B | 7.1B | 6.12B | 6.14B | 6.63B | 9.27B | 9.34B |
Long-Term Debt | 6.52B | 6.24B | 5.96B | 5.82B | 7.1B | 6.12B | 6.14B | 6.61B | 8.57B | 8.58B |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.1M | 33M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 18.9M | 0 | 0 | 2.5M | 900K | 12.08M | 682.61M | 766.46M |
Total Liabilities | 6.9B | 6.82B | 6.31B | 6.12B | 7.27B | 7.29B | 6.3B | 7.88B | 9.91B | 9.88B |
Total Debt | 6.8B | 6.52B | 6.24B | 5.82B | 7.1B | 7.12B | 6.14B | 7.61B | 8.95B | 8.96B |
Net Debt | 5.42B | 4.6B | 5.99B | 4.81B | 5.56B | 5.41B | 5.66B | 6.68B | 8.33B | 8.37B |
Debt / Equity | 1.52x | 1.43x | 1.02x | 0.59x | 0.69x | 0.75x | 0.61x | 0.74x | 0.92x | 0.90x |
Debt / EBITDA | 6.99x | 4.66x | 2.36x | 3.59x | 4.88x | 22.76x | 3.25x | 4.89x | 5.73x | 5.81x |
Net Debt / EBITDA | 5.57x | 3.29x | 2.26x | 2.97x | 3.82x | 17.28x | 3.00x | 4.29x | 5.33x | 5.43x |
Interest Coverage | 6.43x | 6.42x | 10.16x | 11.84x | 8.47x | 2.22x | 10.08x | 6.90x | 5.30x | 3.37x |
Total Equity | 4.46B▲ 0% | 4.55B▲ 2.1% | 6.14B▲ 34.9% | 9.9B▲ 61.1% | 10.25B▲ 3.6% | 9.53B▼ 7.1% | 10.08B▲ 5.9% | 10.34B▲ 2.6% | 9.71B▼ 6.1% | 9.94B▲ 0% |
Equity Growth % | - | 2.05% | 34.91% | 61.13% | 3.56% | -7.06% | 5.87% | 2.56% | -6.07% | -13.32% |
Book Value per Share | 12.59 | 12.85 | 17.34 | 25.50 | 24.71 | 16.86 | 16.73 | 17.41 | 17.36 | 17.76 |
Total Shareholders' Equity | 4.46B | 4.49B | 6.11B | 4.82B | 5.78B | 5.63B | 6.53B | 6.95B | 6.48B | 6.89B |
Common Stock | 0 | 3.28B | 3.28B | 102K | 106K | 107K | 108K | 108K | 106K | 45K |
Retained Earnings | 0 | 1.22B | 2.83B | 1.92B | 2.26B | 1.96B | 2.52B | 2.85B | 2.36B | 2.51B |
Treasury Stock | 0 | 0 | -4.27M | -2.32M | -2.71M | -2.81M | -2.63M | -2.66M | -2.61M | -2.71M |
Accumulated OCI | 0 | -10.26M | 2.09M | 34.4M | 16.49M | 0 | 0 | 0 | 0 | 63K |
Minority Interest | 0 | 63.87M | 35.88M | 5.08B | 4.47B | 3.9B | 3.56B | 3.4B | 3.24B | 3.05B |
RPRX Cash Flow Statement
Royalty Pharma plc (RPRX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 1.42B | 1.62B | 1.67B | 2.03B | 2.02B | 2.14B | 2.99B | 2.77B | 2.49B | 2.65B |
Operating CF Margin % | 88.76% | 90.16% | 91.9% | 95.87% | 88.12% | 95.83% | 126.89% | 122.33% | 104.69% | - |
Operating CF Growth % | - | 14.1% | 3.02% | 22.04% | -0.84% | 6.27% | 39.36% | -7.32% | -10.08% | -5.86% |
Net Income | 1.34B | 1.52B | 2.46B | 1.7B | 1.24B | 230.06M | 1.7B | 1.33B | 1.32B | 827.6M |
Depreciation & Amortization | 33.27M | 33.27M | 23.92M | 23.06M | 23M | 5.67M | 0 | 0 | 3.85M | 3.64M |
Stock-Based Compensation | 0 | 0 | 0 | 5.43M | 2.44M | 2.17M | 2.36M | 2.34M | 289.89M | 289.38M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.52B | 1.63B | -793.43M | 228.22M | 767.22M | 1.87B | 1.28B | 1.38B | 889.04M | 293.31M |
Working Capital Changes | -1.48B | -1.56B | -24.67M | 75.97M | -16.32M | 32.66M | 5.38M | 53.38M | -17.15M | 882.5M |
Change in Receivables | -84.48M | 111.53M | 159.86M | -400K | -29.14M | -4.74M | -1.52M | -4.55M | -2.36M | -3.73M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 1.35M | 6.5M | -766K | -4.59M | 2.29M | 6.24M | -2.29M | -13.93M | -29.09M |
Cash from Investing | -1.59B | 303.42M | -2.15B | -2.76B | -1.87B | -1.03B | -2.07B | -2.68B | -1.61B | -2.64B |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -452.37M |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | 18.53% |
Acquisitions | -2M | -24.17M | -27.04M | -40.16M | -34.85M | -9.9M | -12.54M | -10.96M | -74.42M | -74.42M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 115M | 0 | -250M | 15.08M | -18.08M | 0 | 29.44M | -49.32M | -175.11M | -211.37M |
Cash from Financing | -123.25M | -1.38B | -1.19B | 1.49B | 385.11M | -944.86M | -2.15B | 361.14M | -1.19B | -517.34M |
Debt Issued (Net) | 907M | -294M | -294M | 680.63M | 1.27B | 0 | -1B | 1.47B | 954.48M | 954.48M |
Equity Issued (Net) | 0 | 0 | -4.27M | 1.91B | 0 | 0 | -304.76M | -229.65M | -1.23B | -568.7M |
Dividends Paid | -735.17M | -814.36M | -739.28M | -397.84M | -285.18M | -333.32M | -358.33M | -376.46M | -378.25M | -387.39M |
Share Repurchases | 0 | 0 | -4.27M | 0 | 0 | 0 | -304.76M | -229.65M | -1.23B | -568.7M |
Other Financing | -295.08M | -270.74M | -154.08M | -704.36M | -602.24M | -611.53M | -485.67M | -503.97M | -534.81M | -515.73M |
Net Change in Cash | -292.65M▲ 0% | 542.64M▲ 285.4% | -1.68B▼ 409.2% | 762.48M▲ 145.4% | 532.37M▼ 30.2% | 169.7M▼ 68.1% | -1.23B▼ 827.0% | 452.02M▲ 136.6% | -310.33M▼ 168.7% | -501.32M▲ 0% |
Free Cash Flow | 1.42B▲ 0% | 1.62B▲ 14.1% | 1.67B▲ 3.0% | 2.03B▲ 22.0% | 2.02B▼ 0.8% | 2.14B▲ 6.3% | 2.99B▲ 39.4% | 2.77B▼ 7.3% | 2.49B▼ 10.1% | 2.65B▲ 0% |
FCF Margin % | 88.76% | 90.16% | 91.9% | 95.87% | 88.12% | 95.83% | 126.89% | 122.33% | 104.69% | 108.74% |
FCF Growth % | - | 14.1% | 3.02% | 22.04% | -0.84% | 6.27% | 39.36% | -7.32% | -10.08% | -1.71% |
FCF per Share | 4.00 | 4.57 | 4.71 | 5.24 | 4.86 | 3.80 | 4.96 | 4.66 | 4.45 | 4.74 |
FCF Conversion (FCF/Net Income) | 1.17x | 1.17x | 0.71x | 2.09x | 3.26x | 50.06x | 2.63x | 3.22x | 3.23x | 3.21x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RPRX Key Ratios
Royalty Pharma plc (RPRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 30.57% | 43.92% | 12.16% | 6.15% | 0.43% | 11.57% | 8.41% | 7.69% | 8.54% |
Return on Invested Capital (ROIC) | 10.76% | 18.49% | 8.92% | 7.03% | 1.5% | 7.3% | 5.92% | 6.67% | 6.72% |
Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 74.15% |
Net Margin | 76.76% | 129.45% | 45.94% | 27.07% | 1.91% | 48.2% | 37.95% | 32.42% | 33.9% |
Debt / Equity | 1.43x | 1.02x | 0.59x | 0.69x | 0.75x | 0.61x | 0.74x | 0.92x | 0.90x |
Interest Coverage | 6.42x | 10.16x | 11.84x | 8.47x | 2.22x | 10.08x | 6.90x | 5.30x | 3.37x |
FCF Conversion | 1.17x | 0.71x | 2.09x | 3.26x | 50.06x | 2.63x | 3.22x | 3.23x | 3.21x |
Revenue Growth | 12.33% | 1.08% | 16.98% | 7.87% | -2.28% | 5.24% | -3.86% | 5.06% | 7.82% |
Related:RPRX Dividend History·RPRX Revenue History·RPRX Price History·RPRX P/E History·RPRX Financial Ratios·RPRX Institutional Holders
RPRX SEC Filings & Documents
Royalty Pharma plc (RPRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
RPRX Frequently Asked Questions
Royalty Pharma plc (RPRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Royalty Pharma plc (RPRX) reported $2.44B in revenue for fiscal year 2025. This represents a 53% increase from $1.60B in 2017.
Royalty Pharma plc (RPRX) grew revenue by 5.1% over the past year. This is steady growth.
Yes, Royalty Pharma plc (RPRX) is profitable, generating $827.6M in net income for fiscal year 2025 (32.4% net margin).
Dividend & Returns
Yes, Royalty Pharma plc (RPRX) pays a dividend with a yield of 1.28%. This makes it attractive for income-focused investors.
Royalty Pharma plc (RPRX) has a return on equity (ROE) of 7.7%. This is below average, suggesting room for improvement.
Royalty Pharma plc (RPRX) generated $2.65B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.